ILMN Stock Recent News

BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide.

SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its business, operate responsibly, and lead with integrity.

Statewide Practice Continues to Enhance Genomic Testing to Advance Cancer Care, Improve Cure Rates and Enhance Patient Experience FORT MYERS, Fla., June 9, 2025 /PRNewswire/ -- Liquid biopsy, a blood test that swiftly detects signs of cancerous tumors and cells traveling in the bloodstream, is now available at Florida Cancer Specialists & Research Institute, LLC (FCS), offering significant benefits in the diagnosis and treatment of many of the most common cancers, particularly those in advanced stages. Liquid biopsy is used increasingly to assess lung, colorectal, breast and prostate cancer as well as cancers of the blood. "Liquid biopsy is especially effective for providing genetic information quickly for various types of advanced cancers to help physicians assess and better target treatments that may work best and monitor patient response," said Jennifer Gass, PhD, associate director of the FCS Genetics Laboratory. Biopsies are the definitive method for confirming the presence of can

ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases.

Illumina, Inc. (NASDAQ:ILMN ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 2:30 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participants Eve Burstein - Bernstein Eve Burstein All right. Thank you so much, everyone, for joining.

Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.

Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illumina's IVD portfolio will also expand to offer Pillar oncoReveal® CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeq™ Dx System SAN DIEGO , May 28, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more patients with cancer.

ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum. Illumina Protein Prep 9.5K™ utilizes slow off-rate modified.